Protara Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on the stock and has a $23.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding Protara Therapeutics’ promising developments in their lymphatic malformation (LM) program. The company’s TARA-002, a formulation of OK-432, is being developed for treating macrocystic and mixed lymphatic malformations, which currently have no approved therapies. Historical data from OK-432’s use in over 3,000 pediatric cases globally has shown both safety and durable efficacy, and early data from TARA-002 has mirrored these results with significant complete and partial response rates.
Furthermore, key opinion leaders (KOLs) have highlighted TARA-002’s potential as a foundational therapy in pediatric vascular anomaly centers, given its mechanism of action that remodels malformed lymphatic tissue through immune modulation rather than destruction. This approach is seen as a significant advancement over existing treatments, which often lead to inconsistent outcomes. The upcoming STARBORN-1 study results are anticipated to confirm TARA-002’s efficacy and tolerability, reinforcing the potential for TARA-002 to become the first approved treatment for LM, thus supporting the Buy rating.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Protara Therapeutics, and Merus. According to TipRanks, Y. Maldonado has an average return of 21.8% and a 60.00% success rate on recommended stocks.